These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21397330)

  • 1. Retrospective review of the relationship between weight change and demographic factors following initial depot medroxyprogesterone acetate injection in adolescents.
    Gerlach LS; Saldaña SN; Wang Y; Nick TG; Spigarelli MG
    Clin Ther; 2011 Feb; 33(2):182-7. PubMed ID: 21397330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population.
    Polaneczky M; Guarnaccia M; Alon J; Wiley J
    Fam Plann Perspect; 1996; 28(4):174-8. PubMed ID: 8853283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormones and weight change.
    Pelkman C
    J Reprod Med; 2002 Sep; 47(9 Suppl):791-4. PubMed ID: 12380408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depot medroxyprogesterone acetate contraception. Metabolic parameters and mood changes.
    Westhoff C
    J Reprod Med; 1996 May; 41(5 Suppl):401-6. PubMed ID: 8725702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depot medroxyprogesterone acetate: implications for weight status and bone mineral density in the adolescent female.
    Bonny AE; Harkness LS; Cromer BA
    Adolesc Med Clin; 2005 Oct; 16(3):569-84. PubMed ID: 16183540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method.
    Bonny AE; Ziegler J; Harvey R; Debanne SM; Secic M; Cromer BA
    Arch Pediatr Adolesc Med; 2006 Jan; 160(1):40-5. PubMed ID: 16389209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.
    Kaunitz AM
    Int J Fertil Womens Med; 1998; 43(2):73-83. PubMed ID: 9609206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight and body fat changes in postpartum depot-medroxyprogesterone acetate users.
    Nyirati CM; Habash DL; Shaffer LE
    Contraception; 2013 Jul; 88(1):169-76. PubMed ID: 23177262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive.
    Pantoja M; Medeiros T; Baccarin MC; Morais SS; Bahamondes L; Fernandes AM
    Contraception; 2010 Feb; 81(2):107-11. PubMed ID: 20103446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections.
    Harel Z; Johnson CC; Gold MA; Cromer B; Peterson E; Burkman R; Stager M; Brown R; Bruner A; Coupey S; Hertweck P; Bone H; Wolter K; Nelson A; Marshall S; Bachrach LK
    Contraception; 2010 Apr; 81(4):281-91. PubMed ID: 20227543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Counseling issues and management of side effects for women using depot medroxyprogesterone acetate contraception.
    Nelson AL
    J Reprod Med; 1996 May; 41(5 Suppl):391-400. PubMed ID: 8725701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL.
    Westhoff C; Jain JK; Milsom I; Ray A
    Contraception; 2007 Apr; 75(4):261-7. PubMed ID: 17362703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of depot medroxyprogesterone acetate contraception in adolescents.
    Davis AJ
    J Reprod Med; 1996 May; 41(5 Suppl):407-13. PubMed ID: 8725703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depot-medroxyprogesterone acetate in anticoagulated patients with previous hemorrhagic corpus luteum.
    Sönmezer M; Atabekoğlu C; Cengiz B; Dökmeci F; Cengiz SD
    Eur J Contracept Reprod Health Care; 2005 Mar; 10(1):9-14. PubMed ID: 16036292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of depot medroxyprogesterone acetate contraception.
    Mishell DR
    J Reprod Med; 1996 May; 41(5 Suppl):381-90. PubMed ID: 8725700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Demographic analysis of post-abortive and interval-administered hormonal contraceptive methods.
    Ertopçu K; Inal MM; Ozelmas I
    Eur J Contracept Reprod Health Care; 2005 Mar; 10(1):1-5. PubMed ID: 16036290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting injectable contraception with depot medroxyprogesterone acetate.
    Kaunitz AM
    Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1543-9. PubMed ID: 8178904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting hormonal contraception: assessing impact on bone density, weight, and mood.
    Kaunitz AM
    Int J Fertil Womens Med; 1999; 44(2):110-7. PubMed ID: 10338269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids.
    Enk L; Landgren BM; Lindberg UB; Silfverstolpe G; Crona N
    Horm Metab Res; 1992 Feb; 24(2):85-9. PubMed ID: 1533383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.